Athira pharma provides 2024 clinical pipeline outlook and business update

Completed enrollment in phase 2/3 lift-ad clinical trial of fosgonimeton as a potential treatment for mild-to-moderate alzheimer's disease and expects topline data in second half of 2024  plans to initiate first-in-human studies of ath-1105 to treat amyotrophic lateral sclerosis in first half of 2024   bothell, wash., jan. 08, 2024 (globe newswire) -- athira pharma, inc. (nasdaq: atha), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided a clinical pipeline outlook and business update for 2024.
ATHA Ratings Summary
ATHA Quant Ranking